Anjin: Rocatinlimab treatment for moderate to severe atopic dermatitis achieves common primary endpoint in research

On March 8th, Anjin Company and Concord Kirin Co., Ltd. announced the latest results of the ROCKET Phase III clinical trial project. The project is evaluating the efficacy of rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, for the treatment of moderate to severe atopic dermatitis (AD). The IGNITE study evaluated two dose intensities of rocatinlimab, achieving a common primary endpoint and all key secondary endpoints. Both dose groups showed statistically significant differences compared to the placebo group.